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Yago Nieto, Elizabeth J. ShpallExploration of high-dose chemotherapy (HDC)
for metastatic breast cancer (MBC) began in the mid
1980s, stimulated by Frei’s preclinical studies demon-
strating a steep dose-response effect for DNA-
damaging drugs [1]. The first clinical trial of HDC
for MBC, published in 1986 by Peters and colleagues
[2], included patients with refractory disease treated
with cyclophosphamide/cisplatin/BCNU (STAMP I)
and resulted in the highest response and complete
response rates reported to that date in MBC. Subse-
quent phase 2 trials moved STAMP-I (or other all-
alkylator-based regimens, such as cyclophosphamide/
thiotepa 6 carboplatin) upfront in the treatment of
the disease, targeting less pretreated metastatic pa-
tients as well as patients with high-risk primary breast
cancer (HRPBC). During those years, the introduc-
tion of myeloid growth factors posttransplant, periph-
eral blood progenitor cells (PBPCs) in place of bone
marrow, and other advances in supportive care re-
duced the treatment mortality rate from the initial
15% to 20% to less than 5%. The highly encouraging
results of the early phase 2 trials rapidly prompted ran-
domized phase 3 trials testing the first-generation
HDC regimens. They also generated an unbridled en-
thusiasm among physicians and breast cancer patients
and a premature transfer of stem cell transplant tech-
nology in the 1990s from the academic environment
to community hospitals. Proponents and detractors
of HDC intensely debated in the editorial pages of sci-
entific journals, lay press, and in the courts.
In the middle of this euphoria and raging contro-
versy it became clear that themajority ofMBC patients
still relapsed after HDC. While waiting for the results
of the phase 3 randomized trials, a few academic cen-
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velop more active HDC, by incorporation of new
and potentially more effective drugs [3,4], the design
of sequential multicycle strategies based on the inter-
play of timing, dose, and the appearance of acute
in vivo resistance [5,6], and the development of syner-
gistic combinations of HDC with targeted therapeu-
tics [7]. The second approach aimed at effective and
safe purging of the PBPC grafts of contaminating
breast cancer cells. Initial purging strategies targeted
the tumor cells by pharmacologic or immunomagnetic
methods, and achieved around a 3- to 4-log depletion
of tumor cells [8,9]. These ‘‘negative’’ purging
methods often produced substantial engraft-
ment delays. In contrast, ‘‘positive’’ selection of the
normal stem cells in the graft targeted the CD34 anti-
gen, expressed on both committed and long-term re-
constituting progenitors and not on breast cancer
cells. Using a first-generation immunoadsorption
device, Shpall et al. [10] achieved a 2-log tumor-cell
depletion with comparable engraftment times to those
of patients receiving unmanipulated grafts. A subse-
quent randomized trial comparing CD34-selected
PBPC with a more advanced device, to unselected
PBPC in patients with stage II-IV disease showed
equivalent engraftment times between both groups
[11]. No outcome differences were detected in that
small trial.
In this issue, Muller and colleagues at Stanford re-
port the long-term results of a prospective breast can-
cer phase 2 trial of a positive selection method using
flow-activated cell sorting targeting the CD34 and
Thy-1 antigens, which resulted in a 5- to 6-log tumor
cell depletion [12]. Twenty-two patients with soft tis-
sue, bone, or bone marrow metastases received
STAMP-I followed by highly purified CD341 Thy-
11 PBPC grafts. More than 12 years after the end of
this study, 5 patients are alive, and 4 of them remain
free of progression with normal hematopoietic func-
tion. Although the depth of tumor purging is remark-
able, these results need to be interpreted with several
caveats. Patients with soft tissue/bone/bone marrow
involvement without visceral disease, which is of the
most powerful adverse prognostic factors for HDC
for MBC, can enjoy very prolonged overall and
progression-free survivals. In that light, the retrospec-
tive comparison to a concurrent patient group, one-
third of whom had visceral metastases, treated at the
4 Biol Blood Marrow Transplant 18:1-5, 2012Y. Nieto and E. J. Shpallsame center with STAMP-I and unselected PBPC,
should be interpreted with caution. Importantly, there
is still no convincing evidence of a direct role of occult
tumor cells contaminating PBPC grafts of MBC
patients in posttransplantation relapse. Rather, the
bulk of the data from other studies suggests insuffi-
cient antitumor capacity of the HDC regimen as the
main cause of post-HDC relapse [13,14]. Finally,
most purging methods, including the employed by
the authors, deplete the graft of lymphocytes and slows
CD4 immune reconstitution. Pretransplant immunity
and early postttransplantation immune recovery may
have an important effect on outcome in MBC [15-
18]. Thus, if occult tumor cells in the graft merely rep-
resent a marker of widespreadmicrometastatic disease,
there may be a deleterious effect of purging PBPC
products of MBC patients. It is possible that the opti-
mal scenario to test this purging method might be the
adjuvant setting.
Twenty-five years after that first trial of HDC for
MBC, how does the current article affect the over-
arching evaluation of the use of transplant in breast
cancer? All randomized trials in the MBC and
HRPBC settings, 6 and 15, respectively, have been
analyzed and have largely failed to show an overall
survival benefit from HDC. Although many of those
trials were underpowered to detect realistic survival
differences, the recently published meta-analyses did
not show a global overall survival benefit in either
setting [19,20]. Those overviews, however, detected
a statistically significant 13% decrease of risk of re-
lapse in HRPBC and a 24% decrease of risk of pro-
gression in MBC. The use of HDC for breast
cancer has almost ceased with no registered active tri-
als in the United States. In our view, the data do not
justify the abandonment of the transplant approach to
breast cancer, whereas, in the article authors’ own
words, there is an immense need for curative treat-
ment strategies for its advanced stages. Clearly, a frac-
tion of patients may benefit from a high-dose
approach, such as those with oligometastatic disease
[21]. Personalized medicine has reemphasized the im-
portance of evaluating small subsets of patients that
achieve uncommon benefit following a novel treat-
ment. For example, many trials of HDC for MBC
demonstrated that 5% to 15% patients with advanced
disease experienced .5-year relapse-free survival. If
a substantial fraction of these patients continue in re-
mission 10 to 15 years later, might this observation
suggest a reexamination of the ‘‘incurability’’ of met-
astatic breast cancer for a small and undefined group
of patients? These types of long-term follow-ups, as
in the current article, should be reported. It would
be of interest if personalized medicine concepts in-
duce a reexamination of the importance of the
‘‘tail’’ of the Kaplan-Meier curves, which might re-
flect a subset of cured patients.ACKNOWLEDGMENTS
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